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Abstract
Background: Summary measures of population health are increasingly used in different public health reporting
systems for setting priorities for health care and social service delivery and planning.
Disability-adjusted life years (DALYs) are one of the most commonly used health gap summary measures in the
field of public health and have become the key metric for quantifying burden of disease (BoD).
BoD methodology is, however, complex and highly data demanding, requiring a substantial capacity to apply,
which has led to major disparities across researchers and nations in their resources to perform themselves BoD
studies and interpret the soundness of available estimates produced by the Global Burden of Disease Study.
Methods: BoD researchers from the COST Action European Burden of Disease network reflect on the most
important methodological choices to be made when estimating DALYs. The paper provides an overview of eleven
methodological decisions and challenges drawing on the experiences of countries working with BoD methodology
in their own national studies. Each of these steps are briefly described and, where appropriate, some examples are
provided from different BoD studies across the world.
Results: In this review article we have identified some of the key methodological choices and challenges that are
important to understand when calculating BoD metrics. We have provided examples from different BoD studies
that have developed their own strategies in data usage and implementation of statistical methods in the
production of BoD estimates.
Conclusions: With the increase in national BoD studies developing their own strategies in data usage and
implementation of statistical methods in the production of BoD estimates, there is a pressing need for equitable
capacity building on the one hand, and harmonization of methods on the other hand.
In response to these issues, several BoD networks have emerged in the European region that bring together
expertise across different domains and professional backgrounds. An intensive exchange in the experience of the
researchers in the different countries will enable the understanding of the methods and the interpretation of the
results from the local authorities who can effectively integrate the BoD estimates in public health policies,
intervention and prevention programs.
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Background
Summary measures of population health (SMPH) are
gaining popularity in the recent years and are increas-
ingly used in different public health reporting systems as
an input for setting priorities for health care and social
service delivery and planning.
SMPH can be broadly divided in two groups – indica-
tors for health expectancies and health gaps [1]. A health
expectancy indicates which part of the total life expect-
ancy is spent in good health, and includes measures of
healthy life expectancy [2]. A health gap quantifies the
difference between the actual health of a population and
some stated norm or goal for population health [1]. Each
of these summary measures has a wide-range of subset
measures that has been further developed and imple-
mented in the last few decades.
Disability-adjusted life years (DALYs) are one of the
most commonly used health gap summary measures in
the field of public health and have become the key
metric for quantifying burden of disease (BoD) [3–5].
The DALY metric quantifies the gap between a life lived
in perfect health and the current health status, as the
number of healthy life years lost due to illness (Years
Lived with Disability, YLDs) and premature death (Years
of Life Lost, YLLs). The DALY also allows for monitor-
ing changes in the health of a given population and for
comparing the health of different populations. BoD stud-
ies are becoming increasingly popular and their indica-
tors are used as a means to influence national and local
policy decisions. Driven by the Global Burden of Disease
(GBD) projects initiated in the early 1990s, the DALY
has become the dominant SMPH in BoD studies.
Since 2010 the Institute for Health Metrics and Evalu-
ation (IHME) publishes regular updates of the GBD
study for the entire world [6]. IHME is subsequently and
continuously developing and improving their method-
ology and data recruitment for estimating the DALYs
along with all the other main components. For 2019
GBD will report estimates on premature death and dis-
ability for more than 350 diseases and injuries (including
more than 1200 disease sequelae) and will estimate the
contribution of 87 risk factors to this disease burden [7].
The coverage of diseases and risk factors is a dynamic
process and is extended with each of the study updates.
Driven by the impact of the GBD study, many coun-
tries across the world have adopted the BOD approach,
producing independent DALY estimates or building on
the work of the World Health Organization (WHO) and
IHME [8–11]. Despite the increasing prominence of the
BoD approach, several challenges remain. The BoD
methodology is complex and highly data intensive,
which has led to major disparities across researchers and
nations in their capacity to perform BoD studies, to in-
terpret the soundness of available BoD estimates, or to
advocate for the use of BoD methods [12]. BoD as a gen-
erally standardized approach nonetheless requires differ-
ent methodological choices, and lack of harmonization
in these may hamper comparisons across studies.
In response to these needs, several countries and BoD
researchers have set up ad hoc partnerships. In 2016, the
WHO Regional Office for Europe (WHO-EURO)
launched a European BoD network, aiming to intensify
links between WHO, IHME and the WHO-EURO mem-
ber states [13]. More recently the EU COST Action Bur-
den of Disease network was established to serve as a
technical platform to integrate and strengthen capacity
in BoD assessment across Europe and beyond [12]. One
of the key aims of the network is to provide a platform
to support methodological insights and advances in per-
forming national BoD studies.
Aims
In this paper, experts from the COST Action Burden of
Disease network reflect on some of the key methodlogi-
cal challenges and decisions in performing BoD studies.
The content of this paper has been organized to reflect
as far as possible the sequential steps which need to be
followed to carry out a national BoD study (Table 1).
The paper is not striving to describe all the calculation
steps to estimate DALYs, but rather to outline some of
the most important steps and decisions to be undertaken
in a stepwise approach.
In highlighting the methogological challeges and
decisions required in undertaking a BoD study as well
as providing examples from individual countries in
how they have addressed these challenges, this paper
will identify the key challenges with the aim of work-
ing towards a joint BoD research agenda. This in-
cludes an identification of common challenges as well
as knowledge and data gap, harmonizing methods
and making BoD estimates more accessible to policy-
makers.
Estimation of YLLs
One component of the DALY metric is the measure of
premature mortality or YLL. It can also be used as a
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standalone measure. The concept of YLLs is to esti-
mate the additional length of time a person is ex-
pected to have lived, had they not died prematurely
of a certain disease or injury. The YLLs are based on
relating the age of death to an external standard life
expectancy curve, and can incorporate time discount-
ing and age weighting [14]. Furthermore, YLLs can
be calculated for specific causes of death. In this way
the indicator can be used to compare the relative
importance of different causes of death within a par-
ticular population [15]. Thus, it can be used by
health planners to define priorities for (preventive)
interventions. The calculation of the YLLs is straight-
forward and incorporates the multiplication of the
numbers of death in a reference year for a specific
cause of disease or injury (d) with the remaining life






i = each age (group) from 1 to n
d = number of deaths in each age (group) i
l = standard life expectancy at age of death i (in years)
However, the process of calculating the YLLs involves
several data processing steps which include preparing
the cause of death statistics in a form that can be used
for the calculations (e.g. assessing the completeness of
death reporting), and cleaning the data (e.g.
redistribution of garbage codes). Some of the most
significant steps will be described in the following
section.
Quality of mortality data and definition of ill-defined
deaths
The main prerequisite for estimating YLLs is the
availability of high quality mortality data. Usually
countries with functioning vital registration systems
have data with good quality and high population
coverage. However, countries that do not have good vital
registration systems need to perform some further
efforts for obtaining mortality data. The World Health
Organization (WHO) recommends the following steps
[16]:
1. collation of all available data sources: health
surveys, hospital discharges, medical registries,
police records, etc.;
2. definition of a list of diseases (number of
diseases that has to be analyzed in detail);
and
3. following the list of selected diseases, estimation of
mortality rates by cause, age and sex
For countries with vital registration systems, cause
of death statistics coded using the WHO
International Statistical Classification of Diseases and
Related Health Problems (ICD) [17], contain valuable
information on mortality in the general population.
These statistics can be used in public health policy to
identify the most important causes of death and to
develop interventions and prevention policies.
However, the cause of death statistics may contain
mistakes made during data generation or have
inaccurately coded deaths. Furthermore, the ICD
classification system contains unknown or imprecise
causes of deaths, which are termed as garbage codes
in the GBD study. Others have preferred to describe
such deaths as ‘ill-defined’ [18]. Such ill-defined
deaths (IDDs) can include, for example, ICD codes
that are not possible in certain age groups or sexes
(for instance Alzheimer disease in infant ages, or tes-
ticular cancer in women); inaccurately coded deaths
which may involve ICD codes that are not inform-
ative enough for public health policies (for instance
unspecified cancer type). In many cases such IDDs
may have been unavoidable as the underlying cause
of death was not known to the medical person who
diagnosed the death as it is not always possible to
undertake extensive investigation to establish an exact
cause of death [19].
The percentage of IDDs in the different countries
can vary considerably: a recent study showed that for
Table 1 Key methodological steps in calculation of burden of disease
Years of life lost to premature mortality Years of life lived with disability Disability Adjusted Life Year
Mortality data and definition of ill-defined deaths Definition of disease Age weighting and time discounting
Redistribution of ‘garbage codes’/ill-defined deaths Counting disease frequency Dealing with uncertainty in estimates
Choice of life table Usage of disability weights Choice of standard population
Application of severity distributions
Multimorbidity corrections
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six high-income countries the IDDs varied from 22
to 36% [20]. Studies in Poland and South Korea have
reported over a quarter of the cases in the cause of
death statistics were IDDs [21, 22]. In contrast, in
other countries, such as the Netherlands and
Scotland, IDDs are approximately 10% of all causes
of death [18, 23].
As in the context of BoD studies, all deaths must
be assigned to one specific (and valid) cause of
death, it is necessary to redistribute these IDDs
accordingly. Alternatively, instead of a redistribution,
the IDDs may be gathered in a rest category group
[24]. However, most of the BoD studies opt for a
redistribution of the IDDs. How this is done depends
much on the countries’ death registration system
and the information it collects on the underlying
cause of death and other contributory factors/diseases.
According to the availability of such information,
different methods of redistribution of IDDs can be
used.
Methods of redistribution of ill-defined deaths
IHME uses a very sophisticated and comprehensive
algorithm that defines a set of IDD types for the GBD,
each of which is redistributed to a number of
meaningful causes within each age and/or gender strata
[25]. Where the cause of death is ill-defined the process
aims to estimate the most probable cause of death
based on the literature, expert opinion, ICD rules,
and knowledge about the distribution of diseases in a
country. Methods used for this redistribution include
regression models, fixed proportions, proportional re-
assignment, and fractional assignment of a death
assigned to multiple causes [26]. Up until recently,
the algorithm used in GBD was based exclusively on
the underlying cause of death recorded in the death
certificate, alongside age and gender of the deceased.
However for GBD 2017, IHME developed an algo-
rithm for redistribution of garbage codes based on
multiple causes of death i.e. the underlying cause of
death as well as intermediate and immediate causes
in the death chain. This approach was implemented
in redistribution for a few selected causes e.g. misas-
signment of deaths due to drug overdoses to uninten-
tional poisoning [27].
Due to the complexity of GBD redistribution
methodology and difficulties in replicating the approach,
some national BoD studies have sought to deal with the
redistribution of IDDs using the available cause of death
data in their country [28, 29]. Mostly the development
of country specific methodology is driven by the
available data in the given country. As an example, in
information Case example 1 is presented a case study
from Australia.
Case example 1: Redistribution of Ill-defined deaths. A case study from
Australia
The most recent Australian BoD Studies [11, 30], conducted by the
Australian Institute of Health and Welfare (AIHW), have used Australian
data to develop methods for the redistribution of deaths.
The first method uses direct data on plausible alternative causes of death
for the deaths identified for redistribution. It uses information obtained
through data linkage studies, sourced from deaths coded independently
by cancer registries, and available on coroner-certified deaths and is
considered the best method to use when suitable data are available.
The second method (termed the Indirect multiple causes of death
(MCoD) method) uses algorithms based on Australia’s multiple cause of
death statistics. It is used for the most commonly occurring causes of
death (e.g. heart failure, septicaemia, pneumonitis and hypertension)
where no direct data is available. This method uses the pattern of the
underlying causes of death (UCoD) where the cause identified for
redistribution was mentioned as an associated cause of death. The
corresponding UCoDs and their proportional distribution provide the
redistribution algorithm.
The third method, which uses proportional redistribution to specified
target cause(s), is only used when neither of the other methods described
above are suitable. This method reassigns deaths across a range of target
causes selected according to: the existing distribution of underlying cause
of death within that disease group, expert advice, or the GBD
redistribution algorithms if considered appropriate for Australia [11].
Using the Australian redistribution methods, approximately 10% of deaths
were identified for redistribution in 2010. This compares with 18% of
Australian deaths that were identified using GBD algorithms. The difference
is largely due to the cause list used: some of the causes of death that were
redistributed in the GBD study were directly allocated to a specified cause
in the Australian study [30]. The largest numbers of deaths gained by
redistribution in the 2015 Australian study were for cardiovascular diseases
(5081 more deaths, an increase of 11%), cancer (4956 more deaths, an
increase of 11%) and endocrine disorders (1648 more deaths, an increase
of 46% largely due to deaths coded to unspecified diabetes being
reassigned to Type 1, Type 2 and Other diabetes) [11].
Choice of life table
After the redistribution procedure of the cause of death
statistics, information on the exact number of deaths for
each cause of death for each age group and sex (possibly
by region) is available. The next step for calculating the
YLLs is choosing an appropriate life expectancy. The life
expectancy within a country can be extracted from the
national life tables.
Life tables are the means of translating age-specific mor-
tality estimates into estimates of YLLs [3]. Life tables, also
referred to as mortality or actuarial tables, use estimates of
mortality rates and population counts to estimate period
or cohort life expectancies. The remaining life expectancy
at defined ages or age categories is required for use in
BoD studies to facilitate YLLs calculations. There are two
distinct issues which may affect end estimates:
 age categorisation and
 the expected value of remaining life years assigned
at age of death.
von der Lippe et al. Archives of Public Health          (2020) 78:137 Page 4 of 14
Across BoD studies, both age-categorised and single-
year life table approaches have been widely utilised. This
choice is largely dependent on the availability of source
data, as granular individual-level data on deaths is re-
quired to make use of single-year life tables. The impact
of this choice is likely to be insignificant on final esti-
mates, if one assumes J-shaped mortality rate curves by
age. However, it is likely to be larger the earlier the final
open-ended age-group starts, as the cut-off will deter-
mine how the mortality rate exponentially increases.
The major issue which impacts on the YLLs calculated is
the value of remaining life years which is assigned at age of
death. This has a significant impact on burden estimates
and has important ethical distinctions [31]. There are three
main methods which can be used to determine the value of
remaining life years at a given age of death:
 Use of aspirational life table
 Use of observed or national life tables
 Using a fixed value
The first method is the use of an aspirational life table,
such as used in the GBD study, which is referred to as
the ideal standard [3]. Many other national studies, such
as those in Australia, New Zealand and Turkey [32–34]
have adopted this approach. A second approach is to use
observed, or national life tables, which can be calculated
from source data and are representative of the
populations for which estimates are being reported.
Countries such as Estonia, Austria, and Scotland have
utilised this approach in their national studies [30, 35,
36]. Between these two approaches, evidence has
illustrated the impact of how rates of DALYs and ranks
of causes are affected. This choice directly affects deaths
and has large implications for how we value YLLs in
relation to YLDs [37]. Aspirational or standard life tables
are a good way to facilitate comparisons between
countries, as they perform a similar function as to when
rates are standardised. Comparisons between observed,
or national, life tables are difficult to be made between
countries and even across time because no standard has
been developed. The criticism of aspirational life tables
is that they are not pragmatic, which is what observed
life tables are seen to represent. Although there may be
ethical implications of using stratified life tables that give
different values of remaining life to different subgroups.
These considerations are less of an issue if the study is
cross-sectional in nature and seeks to describe population
health loss without considerations of comparisons over
time and across locations. From a methodological per-
spective, a standard must be set to enable comparisons
and aspirational life tables are beneficial in this regard be-
cause there are always a subset of preventable deaths and
improvement can always be strived towards [15].
The third and final approach is to determine the
remaining life years at age of death based on a fixed
value. This is a former method usually referred to as
years of potential life lost (PYLL), which would assign a
fixed value, such as 75 years, and determine the number
of years lost based on the difference between 75 and the
age of death with any deaths beyond age of 75 being
assigned to the value of 0. The fixed value is most
commonly set at a value which would be desirable, or
realistic, for people to live to or an age below which
mortality is considered preventable but ultimately the
choice of a fixed value does remain arbitrary. Although
this approach could be combined with an aspirational
approach to suggest that people could live to older ages,
such as the oldest reported death which occurred at 122
years of age [38].
Within the COST Action European Burden of Disease
network [12] there is a consideration to establish a
standard European life table where the highest observed
life expectancy for each age group across all European
countries is included. In this way comparisons between
those countries can be easily conducted and there will
be higher acceptance on national levels compared to the
global aspiration life table.
Estimation of YLDs
The other component of the DALY metric is the YLD,
which measures the healthy time that is lost because of
living with a disease or injury. YLDs are calculated by
multiplying the prevalence or incidence of a disease by
the short- or long-term loss of health associated with
that disability (the disability weight), the disease duration
and disease severity (severity distribution), respectively.





I is the number of incident cases in the reference period,
DW is the disability weight (in the range 0–1),




P is the number of prevalent cases in the reference period,
DW is the disability weight (in the range 0–1),
S is the severity proportion.
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The process of calculating a YLD involves several
components and requires extensive epidemiological
modelling and is often based on a diverse range of data
sources, literature research, and/or expert opinion. In
this section we will describe some of the key
methodological challenges in calculating YLDs including
the choice of data sources to estimate disease frequency,
disability weights, severity distributions and adjusting for
multimorbidities.
Epidemiological estimates
Unlike cause of death information which largely relies
on one data source, estimating YLDs will depend on a
wide range of different data sources specific to each
disease. It requires judgment on what the most plausible
source of information is, or how different sources could
be combined, and which parameters best describe the
disability caused by each disease [16], Table 2.
Unlike mortality data, there is often no single
comprehensive and reliable source of data on incidence,
prevalence, severity and duration of all non-fatal health
conditions. Ideally, one would like to have data from a
nationally representative system that continuously moni-
tors the occurrence of all disorders in the population,
based on a set of clearly defined diagnostic criteria. In-
stead, disease and injury morbidity estimates tend to be
drawn from a wide variety of sources relying on what is
available to describe the disease epidemiology. Prefera-
bly, disease estimates should be based on the best
sources available, and should have case definitions ap-
propriate to the disease being analysed [16, 28, 39].
Ideally, the necessary data should be collected through a
systematic review of peer-reviewed literature and various
sources of grey literature, including government agen-
cies, non-governmental organizations and academia. Ex-
amples of the range of data sources that could be
explored are provided in Table 3.
Administrative data sources (for example, disease
registers, hospitalisations) can be evaluated for their
level of ascertainment and coverage. Surveys can be
assessed for their representativeness, potential selection
bias and measurement bias (validity and reliability of
measurement). Epidemiological studies should be
evaluated for the quality of their study design, their
timeliness, credibility, representativeness and sources of
bias or error. All potential data sources (whether
published or unpublished) should be assessed for their
comparability, relevance and representativeness,
currency, accuracy, validation, credibility and
accessibility/ timeliness [39].
The availability of suitable data sources will often
determine the scope of the BoD study. Countries
embarking on a comprehensive BoD will face problems
with data gaps. Some diseases are easier to cover than
others based on data available in specific countries.
There are few examples of countries who have
conducted a full national BoD study covering a
comprehensive range of conditions (e.g. Australia, the
Netherlands) [40, 41]. A review of BoD studies carried
out in the European Union found that 85% (169/198) of
studies covered in review looked at a small range of
diseases or just risk factors and often for specific
research purposes only [8]. For instance, the Serbian
BoD study includes 18 selected diseases and 7 risk
factors [42], the Scottish BoD investigates 132 diseases
and injuries [30] and the Netherlands’ study covers 101
diseases and injuries [43]. Furthermore, studies
concentrating only on one or few diseases are also
performed frequently [39, 44]. Other studies provide
more detailed estimates for subgroup populations of
interest. For instance, the Australian BoD study
produces estimates for states and territories, by
remoteness areas, by socio-economic group and for Indi-
genous and non-Indigenous Australians [32].
To date, the two most comprehensive sources of
morbidity estimates for many countries are the most
recent GBD studies conducted by IHME and the WHO.
The GBD study provides a standardised approach for
estimating incidence, prevalence, and YLDs by cause,
age, sex, year, and location [25], where the methods used
are continuously improved with each iteration. The
Table 3 Possible data sources
• Hospital statistics, including inpatient, outpatient attendances
emergency department attendances
• Maternity, birth records and Neonatal Care
• Primary care data
• Disease registers
• Prescriptions
• Population level health surveys
• Communicable disease surveillance
• Published literature
• Grey literature, including government agencies, non-governmental or-
ganizations and academia.
Table 2 Key steps in describing disease epidemiology for
burden of disease studies [16]
• What is the current knowledge on the disease being studied?
• What are the limitations of the current knowledge on the disease
being studied?
• What are the relevant data available on the natural history of the
disease and its disabling sequelae? (prevalence, incidence, duration, age
of onset, remission rate, and mortality rate, level of severity and duration
from disease onset to disabling sequela)?
• If there are no precise data, is there at least a general consensus
amongst disease experts?
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study aims to use all accessible information on disease
occurrence, natural history, and severity that passes a set
of inclusion criteria. In addition to data sources based
on primary literature, surveys, and surveillance, the GBD
study has used an increasing number of hospital
discharge records, outpatient visit records, and health
insurance claims to inform various steps of the non-fatal
modelling process.
The GBD study provides summary of estimates for all
regions and countries of the world from a viewpoint of
global average. However, data sources that are fed into
the modelling process for country-level estimates can
vary based on locations with limited availability of data
[45–47]. This can lead to a high reliance on GBD to fill
data gaps for these locations. The usage of very compli-
cated calculation procedures in the GBD hampers the
replication of the methodology on a country level [41,
48]. All this can limit the use of BoD estimates on a na-
tional level because even though international data com-
parisons provide a basis for policy discussion, policy
makers often require assurance that these estimates are
reliable in the local situation [5]. To address this and
also produce a comprehensive national BoD study, re-
searchers are using the GBD framework but adjusting
certain methodological aspects to tailor it to the needs
of the specific country using counry specific sources e.g.
use of country specific disease classification, use of dis-
ease prevalence data derived from administrative patient
databases instead of survey-based disease incidence esti-
mation and use of national disability weights in accord-
ance with the contextualized disease classification [37,
45, 49–51].
Usage of disability weights
The disability weight is an essential factor to assess the
YLDs because it translates morbidity into a theoretical
survival loss by weighting survival for the time lived with
functional capacity [52]. A disability weight reflects the
impact of a disease or injury on a person’s life. Its value
is anchored between 0 (equivalent to “full health”) and 1
(equivalent to “death”) and is commonly based on the
health state valuations of a group of individuals [1].
Several sets of disability weights exist, such as the sets of
GBD disability weights [3, 53, 54] as well as national sets
[40, 55–58]. The set of GBD disability weights is used
most frequently.
The first large set of global disability weights was
derived for the GBD 1996 study. These disability weights
were derived in a group exercise in which a panel of ten
health experts evaluated 483 health states [3]. The
choice to elicit global disability weights based on health
state valuations of a small group of health experts was
subsequently criticized [59, 60]. In the latest revisions of
the GBD study, disability weights have been based on
the health state valuations of over 60,000 people from
the general public of a large number of countries to
ensure that the disability weights reflected the views of
the global population [54].
Apart from the characteristics of the individuals who
provide the health state valuations, the value of the
disability weight also depends on the description of the
health state and the valuation methods that are used
[61]. Health states can be described in generic terms or
in disease-specific terms. A disease-specific description
depicts the disease label and/or clinical description of
the condition. A generic health state description depicts
the functional health independent of the actual under-
lying condition. Table 4 provides examples of a disease
specific and generic description of moderate to severe
depression. Previous studies have shown that disease-
specific health state descriptions provide information
that is not reflected in the generic health states but that
matters for health state valuation [63, 64]. On the other
hand, disease specific health state descriptions may pro-
duce information bias because of message-framing ef-
fects [65, 66]. For the latest revisions of the GBD study,
health states were described in both generic and disease
specific terms, but without providing the disease label.
An example of a health state description of the 2013 re-
vision of the GBD disability weights is “this person has
constant sadness and has lost interest in usual activities.
The person has some difficulty in daily life, sleeps badly,
has trouble concentrating, and sometimes thinks about
harming himself (or herself)” (Major depressive disorder:
moderate episode) [56].
The valuation methods that have been used to derive
disability weights are the visual analogue scale (VAS),
time trade-off (TTO), person trade-off (PTO) and paired
comparison [61]. The VAS valuation technique requires
participants to score the injury stage on a vertical scale
graded from 0 (worst imaginable health state) to 100
(best imaginable health state). With TTO, the
Table 4 Example of a disease specific and generic description of moderate to severe depression, based on Kruijshaar et al. 2005 [62]
Disease specific description Generic description
This person experiences one or more depressive episodes within a year.
During these periods they go through permanent feelings of sadness or
emptiness and a permanent loss of interest or pleasure in nearly all
activities. He/she has problems eating and/or sleeping and feel worthless
or guilty. He/she may have thoughts of death.
This person has some problems with performing usual activities, feeling
tired, moderate anxiety or depression, some cognitive impairments.
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participants are asked how much time they would be
willing to “trade” in order to be restored from the pre-
sented disease stage to full health. The person trade-off
asks the participant how many outcomes of one kind
(e.g. moderate to severe depression) they consider
equivalent in social value to a set number of outcomes
of another kind. With paired comparisons two descrip-
tions of hypothetical health states are presented to re-
spondents who have to decide which they regard as
being healthier. These valuation methods give informa-
tion about the relative desirability of a health state com-
pared to other health states; however, the properties of
the valuation methods affect the preferences that are
measured. For instance, many studies have found that
health state valuations with the VAS tend to be higher
compared to equivalent valuations with choice-based
valuation methods, such as the TTO and PTO [61, 67,
68]. For the latest revisions of the GBD study, paired
comparison was used to elicit preferences for health
states as well as population health equivalence (PHE)
questions [54]. PHE questions ask for a retrospective as-
sessment that compares two hypothetical health pro-
grams. Responses on population health equivalence
questions were used to locate the health states on a 0–1
disability weight scale.
Severity distributions
Estimates of the frequency of morbidity in a population,
such as prevalence, are transformed into YLDs using
disability weights for each disease-specific sequela. Se-
verity distributions are a means of summarising the
range of health loss suffered due to a disease which en-
ables estimates of disease occurrence to be paired with
disability weights, to estimate YLDs in BoD studies [69].
These distributions are usually expressed as the propor-
tion of cases living with either: mild, moderate, severe,
or no health loss (asymptomatic).
The GBD study applies the same severity distributions
to all countries and regions across the world, which are
largely based on data from three population surveys in the
United States and Australia: the US Medical Expenditure
Panel Survey (MEPS) 2000–2014, the [US] National
Epidemiological Survey on Alcohol and Related Conditions
(NESARC) 2000–2001 and 2004–2005, and the Australian
National Survey of Mental Health and Wellbeing of Adults
(NSMHWB) 1997. Each dataset containes individual-level
measurements of functional health status as well as diag-
nostic information on the conditions affecting each individ-
ual [70]. The GBD study acknowledges concerns over
applying estimates of severity distributions based on data
from the United States and Australia, noting that it is the
only available information that they were able to use
because of inadequate data on severity from surveys or the
epidemiological literature [69, 71].
Users of GBD estimates are, therefore, using an
assumption of fixed severity distributions across
populations. Researchers from independent national
studies have been left with either: using the same
approach as the GBD study; or developing their own
country-specific severity distributions for all, or a subset
of, causes. Pivotal examples of this are found in South
Korea, Germany and Scotland, where researchers have
opted to develop country-specific severity distributions
[49, 72, 73]. A recent study highlighted a potential bias
in point estimates of weighted-average disability weights
created using worldwide cancer severity distributions
[73]. This bias would have led to the misrepresentation
of non-fatal (i.e. YLD) estimates of the burden of indi-
vidual cancers, and underestimation in the scale of so-
cioeconomic inequality in this non-fatal burden.
These issues raise uncertainties over interpreting
YLD estimates, particularly if they are being used to
develop and influence policies and to determine
priorities across diseases and populations. It is clear
that GBD researchers and those carrying out national
studies need to work towards ensuring that estimates
are based upon country-specific data, and, if possible,
that the impact of assumptions are fully tested and
understood [74]. Assessing the leading causes of YLDs
and differences between the highest and lowest health
state disability weights can be used to identify priority
diseases for which it would be most beneficial to fur-
ther develop severity distributions and help under-
stand the wider uncertainties over applicability that
are currently unanswered.
In most cases the estimation of severity distributions
involves complex methodology as data for such
assessments are very limited data or not reliable. When
the appropriate data are obtained, the estimatation of
severity distributions can be straight forward. In
Information Case example 2 is given one example from
the German project BURDEN 2020.
Case example 2: Etimation of severity distribution for migraine and low
back pain. A case study from Germany
Using claims data as a single database to estimate prevalence and
severity distributions for diseases like migraine or low back pain can be
problematic. As usually people do not necessarily seek help from a
physician if they suffer from acute headache or experience acute
episodes of low back pain, there is a certain underreporting in terms of
prevalence of these diseases.
The German project BURDEN 2020, for instance, has conducted an own
survey on migraine, low back pain and neck pain in order to
operationalize the indicators as defined by the GBD study [75]. The
survey enables to report estimates on the prevalence and severity
distributions for each of these diseases. The results have shown that
there are some differences in the country specific severity distribution
compared to the GBD one, even if the same health states are measured.
Furthermore, such an additional study provides the possibility to derive
age and sex specific severity distributions which even further refine the
estimated YLDs.
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Multimorbidity corrections
With an ageing population, the prevalence of
multimorbidity increases. Ignoring multimorbidity (i.e.
co-occurrence of multiple diseases within one person
[76]) results in a possible overestimation of the YLDs
and thus of the overall disease burden [77, 78]. When no
correction for multi-morbidity in an multi-cause BoD
study is performed, then it automatically means that the
disability weights of the comorbid diseases are added up
[79]. This means that the additional effect on disability
of one comorbid disease simply adds to the effect of the
primary disease observed in uni-conditional patients.
This is usually refered to as the additive approach.
To account for multimorbidity, estimates are required
of the prevalence and the severity of combination of
(two or more) diseases. There are several methods to
calculate prevalence of multimorbidity and the
combined disability weights. A systematic comparison of
three different comorbidity adjustment approaches in
patients with injuries and common diseases with non-
trivial health impacts as the secondary condition was
conducted by Haagsma et al. (2011) [79].
The most applied method in BoD studies is to assume
independent prevalence and use a multiplicative model
for combined disability weights [80, 81]. For persons
with several health conditions, the simple additive
approach may be problematic because adding disability
weights on the individual level might lead to an overall
disability above 1. A disability weight above 1 would
imply that a year lived with disability is weighted higher
than a year lost to death. To avoid this, the
multiplicative method achieves a convergence of
combined disability weights towards one [78]. To realize
a data frame on an individual level, a simulated
population is created. In order to reach the same disease
prevalence as the original population subgroup of
interest, diseases are independently assigned to
simulants by assuming disease prevalence to be
probabilities. The assumption of independence ignores
the coexistence of and thus correlations between
diseases. Then the disease burden of each individual in
the simulated population is estimated using the formula:
burden for individual ¼ 1 −
Y
d¼diseases s=he suffers
1 − disability weightd
 
The burden for each simulated individual is later used
to calculate a disability weight that is redistributed for all
the diseases that affect a population subgroup [82]. This
approach leads to a downward correction of around 10%
for 25 chronic conditions. In reality, the assumption of
independent occurrence might be a further
overestimation, since different diseases have often
shared risk factors (e.g. smoking relates to COPD and
lung cancer), or certain diseases increase the risk for
other diseases (diabetes and cardiovascular diseases).
As the multimorbidity adjustment is a complex issue
and highly depends on the number of diseases under
study, many countries have adapted the GBD approach to
perform such corrections in the national studies [11, 83].
In information Case example 3 is described the approach
used in the Netherlands.
Case example 3: Multimorbidity correction. A case study from The
Netherlands
In the Netherlands, an adapted approach is used, where multimorbidity
corrections are performed according to an independently-assumed
occurrence of multiple disease data. This occurrence is calculated by
gender, 5 year age groups, and the selection of long-term and chronic
diseases. Combinations of up to five different diseases are considered.
The multiplicative approach is applied for the disability weight of
multimorbidity combinations [78].
The Estimation of DALYs
The DALYs are simple aggregation of the estimated
YLDs and YLLs:
DALY ¼ YLDþ YLL
As mentioned above, DALYs quantify the health gap
between a life lived in perfect health and current health
status.
Social weighting: age weighting and time discounting
In early GBD studies, two additional social weights,
discounting and age weighting, applied to the calculation
of the final YLLs [14]. In the GBD 2010 study, however,
these social weighting functions were dropped, in order to
simplify the calculation and interpretation of DALYs [6].
Age weighting implies that the value of life depends
on age, such that greater weights are assigned to deaths
at younger ages and lower weights to deaths at older
ages. Age weighting may be used to increase or decrease
the DALYs contributed by various age groups within a
population if some age groups are societally deemed
more “valuable” than others [84]. In early GBD studies,
the weighting peaked at around 25 years, and decreased
as age increased [14]. Discounting is an economic
concept that applies higher weights to benefits that arise
in the present relative to the future [3]. With
discounting, an intervention that prevents 1000 cases of
heart disease this year will remove more DALYs from a
population’s total count of DALYs than an intervention
expected to prevent 1000 cases of heart diseases from
occurring 30 years from now. In the equations used to
estimate DALYs, discounting assigns greater value to
YLL reductions in the present than to years of life
gained in future years [84]. GBD studies from the 1990s
von der Lippe et al. Archives of Public Health          (2020) 78:137 Page 9 of 14
and early 2000s generally recommended using a 3%
discount rate [14].
The use of age weighting and discounting in earlier
GBD studies has been controversially discussed. Many of
the assumptions and value judgements implicit in the
choice of either social weighting were criticised [2, 85,
86]. Subsequently from 2010 onwards, discounting and
age weighting were no longer used in GBD estimates [6,
87, 88]. Age weighting and time-based discounting, how-
ever, are still commonly used in national BoD studies [8,
9, 89, 90]. This can lead to considerable variability in the
estimates of BoD depending on whether age weighing
and discounting are used individually or together which
have led to calls for transparency regarding the type of
metric used and for a generally acceptable method that
incorporates all the relevant social values to be devel-
oped [91].
Dealing with uncertainty
Each estimate cannot be fully accurate and precise
and carries with itself a kind of uncertainty that can
have different sources. Normally, estimates are
reported with confidence intervals or uncertainty
bounds to account for possible inaccuracy of the
estimates. Uncertainties can come from the data
source but also can be produced by the modelling
procedures and assumptions made [92]. As the GBD
estimations involve very complicated methods or use
data that is sometimes limited in its information,
GBD publishes all YLLs, YLDs and DALYs estimates
with uncertainty intervals which attempt to capture
the random and systematic error in disease
estimates.
Uncertainty bounds for all estimates in the GBD are
assessed on each step of the modelling processes and
involve a very complex estimation procedure. The GBD
approach to describing and estimating uncertainty has
been to define them as probability distributions using a
Bayesian interpretation of probability as expressing
uncertainty of an observed or hypothetical event given a
set of assumptions about the world [93]. In GBD 2017,
every estimate was calculated 1000 times, each time
sampling from distributions rather than point estimates
for data inputs, data transformations and model choice.
The 95% uncertainty interval is determined by the 25th
and 75th value of the 1000 values after ordering them
from smallest to largest [71].
Deriving uncertainty in estimated disease burden is,
however, difficult to do, because apart from the large
number and disparate nature of the data sources used,
information or knowledge about the quality of and
potential biases in the data are often limited. Larger
uncertainty intervals can result from limited data
availability, small studies, and conflicting data, while
smaller uncertainty intervals can result from extensive
data availability, large studies, and data that are
consistent across sources. Furthermore, the methods
applied for generating uncertainty intervals in the GBD
are difficult to replicate in other BoD studies. This has
led to the development of own methods of uncertainty
estimation [11, 30]. Example from Scotland is described
in information Case example 4.
Case example 4: Dealing with uncertainty. A case study from Scotland
In order to provide a measure of the degree of accuracy and relevance
of the estimated disease DALYs in the SBoD Study, a measure of data
quality was developed by researchers, similar to that implemented in
Australia [11, 94]. This measure assigns a RAG (Red; Amber; Green) status
to each disease or injury indicative of the accuracy and relevance of the
estimates [94].
The data quality was assessed using the criteria below, on a scale of 1
to 5, with the weighted scores being assessed on a continuous scale:
Morbidity (YLDs and prevalence):
• Relevance and accuracy of the data source used to measure the
population of interest;
• Degree of adjustments performed to the input data;
• Likelihood that the implemented disease model captured the burden
of morbidity based on review of other data on disease prevalence in
Scotland and the United Kingdom and disease expert advice/guidance.
Mortality (YLLs and deaths):
• Contribution of IDDs as a total of all deaths.
DALYs:
• Weighted-average of morbidity and mortality scores, where the
weights were defined as the proportions of YLDs and YLLs of DALYs
for the given cause of disease or injury for all ages and both sexes.
These criteria are subjectively assessed and each criterion is scored on a
scale of 1 to 5. Interpretation of the assigned RAG status is defined as:
Green - highly accurate and relevant: Estimates have been derived using
relevant and robust data sources with only a small degree of
adjustments performed to the input data; Amber - Moderately accurate
and relevant: Estimates have been derived using reasonably relevant
and robust data sources with only a moderate degree of adjustments
performed to the input data; and Red - uncertainties over accuracy and
relevance: Estimates have been derived using less comprehensive or
relevant data sources with a high degree of adjustments performed to
the input data.
Impact from the choice of standard population
The final results of the YLLs, YLDs and DALYs
calculation are usually presented not only in pure
numbers, but also as rates. Rates are calculated because
they frame the frequency of health loss in the
perspective of defined populations. There are two main
methods of rate calculations widely used in BoD studies:
crude; and directly standardised, both of which have
important uses and distinctions.
Crude rates should primarily be used to establish
within-area prioritisation, or for when assessing the rela-
tive contribution of sub-groups across a larger region.
Rates can also be used for monitoring across countries
and temporal changes. Directly age-standardised rates
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(ASR) are required to facilitate this. ASRs use common
reference population age-structure weights to enable the
creation of artificial rates representative of a hypothetical
scenario that would have occurred if the groups being
compared had the same age distribution.
As the GBD study has an international remit, their
ASR estimates are standardised to a world standard
population (WSP). The WHO WSP was used in the first
study iteration [3], with more recent GBD cycles using a
GBD WSP in ASR calculations (GBD 2017). Other
options to standardise rates are available, such as using
the 2013 European Standard Population [93].
The Eurostat task force’s revision of the 2013 ESP
highlighted that the plausibility and validity of ASRs
come into question when residential populations have
excessively different age structures than proposed
standard populations [95]. Recent evidence focusing on
differences between ASRs constructed using the 2013
ESP and GBD WSP illustrated that they were not only
different in scale, but due to the effects of differences in
age-weightings between standard populations there were
significant changes in the rank order of causes [37].
Since the GBD WSP is a younger population than the
2013 ESP, causes that operate early in the life course
would be expected to see relative gains, with those
causes operating later in the life course observing reduc-
tions in ASR. Temporal effects in changing of the rank-
ing of cardiovascular mortality across Europe have also
been previously reported [96], highlighting that these is-
sues are not only prevalent when assessing different
causes of disease, but also across locations over time.
This evidence means that there may be significant issues
in knowledge translation for national BoD studies to
consider, when crude and ASR estimates become exces-
sively different.
Summary and future developments
BoD studies provide a unique perspective on health, one
that integrates fatal and nonfatal outcomes, yet also
allows the two classes of outcomes to be examined
separately. In addition, BoD analyses provides invaluable
information that will assist in taking up the future
challenges posed by an aging population, by changes in
disease and risk factor patterns, and by the increasing
costs of health services.
Driven by the impact of the GBD study, many
countries have and initiated BoD studies for specific
causes and/or geographies [8, 9]. The increasing
prominence of the BoD approach, however, comes at a
cost. The BoD methodology is complex and highly data
demanding, requiring a substantial capacity to apply,
which has led to major disparities across researchers and
nations in their capacity to perform themselves BoD
studies, interpret the soundness of available BoD
estimates produced by IHME and others, or advocate for
the use of BoD metrics.
In this review article we have identified some of the
key methodological choices and challenges that are
important to understand when calculating BoD metrics
(YLLs, YLDs and DALYs). We have provided examples
from different BoD studies that have developed their
own strategies in data usage and implementation of
statistical methods in the production of BoD estimates.
As more and more countries are implementing or
using the BoD approach, there is an increasing need for
equitable capacity building on the one hand (including
an improved understanding of the complex methods
behind IHME and other burden estimates), and
harmonization of methods on the other hand.
Furthermore, current evolutions in public health,
including big data and precision public health, call for a
technical platform to foster the integration of these
concepts in the BoD approach. This problem is
acknowledged by all researchers involved in BoD studies
and it is increasingly recognised that there is a high need
for knowledge transfer, capacity building and putting
joint efforts together in improving the methodology and
statistical modelling.
The COST Action European Burden of disease
network has been established to provide a technical
platform to integrate and strengthen capacity in BoD
assessment across Europe and beyond [12]. One of
the aims of the network is to provide a checklist and
a road map for conducting BoD study which may
allow a comparison between the national BoD studies
in the future. Furthermore, an intensive exchange in
the experience of the researchers in the different
countries will enable the understanding of the
methods and the interpretation of the results from
the local authorities who can effectively integrate the
BoD estimates in public health policies, intervention
and prevention programs.
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